Načítá se...
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
OBJECTIVE: To assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately‐to‐severely active rheumatoid arthritis (RA). METHODS: Data were poo...
Uloženo v:
| Vydáno v: | Arthritis Rheumatol |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6618316/ https://ncbi.nlm.nih.gov/pubmed/30663869 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40841 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|